Cargando…

Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer

BACKGROUND: Quantitative differences in biomarker expression relative to age and molecular subtypes have not been well documented in invasive breast cancer (IBCA). METHODS: Oestrogen receptor (ER), progesterone receptor (PR), HER2, ki67, p53 and DNA ploidy was performed by image analysis in 162 cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, D H, Rahardja, D, King, E, Peng, Y, Sarode, V R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394967/
https://www.ncbi.nlm.nih.gov/pubmed/22713661
http://dx.doi.org/10.1038/bjc.2012.219
_version_ 1782237911452745728
author Morrison, D H
Rahardja, D
King, E
Peng, Y
Sarode, V R
author_facet Morrison, D H
Rahardja, D
King, E
Peng, Y
Sarode, V R
author_sort Morrison, D H
collection PubMed
description BACKGROUND: Quantitative differences in biomarker expression relative to age and molecular subtypes have not been well documented in invasive breast cancer (IBCA). METHODS: Oestrogen receptor (ER), progesterone receptor (PR), HER2, ki67, p53 and DNA ploidy was performed by image analysis in 162 consecutive IBCAs in women (⩽40 years) and compared with women ⩾50 years (100 cases). Molecular subtypes were defined by immunohistochemistry (IHC). RESULTS: Among young women, tumours were frequently ER negative (P=0.01) with lower ER (P<0.00), PR (P=0.03), higher ki67 index (KI) (P=0.01) and p53 (P=0.00) compared with older women. Triple negative was more frequent among young women with frequent lymph node involvement compared with older women. Luminal B among young vs old women showed lower ER (67% vs 88%), PR (32% vs 52%), higher KI (48% vs 34%) and p53 (19% vs 7%). Linear regression model showed increasing KI (P<0.0001) and p53 (P=0.0003) according to the molecular subtypes. Survival difference among subtypes was demonstrated by multivariate analysis (P=0.0092) after adjusting for age, race, tumour size, grade and stage. CONCLUSION: We demonstrated significant differences in biomarker expression relative to age and molecular subtypes. Molecular subtype defined by IHC was an independent prognostic factor.
format Online
Article
Text
id pubmed-3394967
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33949672013-07-10 Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer Morrison, D H Rahardja, D King, E Peng, Y Sarode, V R Br J Cancer Molecular Diagnostics BACKGROUND: Quantitative differences in biomarker expression relative to age and molecular subtypes have not been well documented in invasive breast cancer (IBCA). METHODS: Oestrogen receptor (ER), progesterone receptor (PR), HER2, ki67, p53 and DNA ploidy was performed by image analysis in 162 consecutive IBCAs in women (⩽40 years) and compared with women ⩾50 years (100 cases). Molecular subtypes were defined by immunohistochemistry (IHC). RESULTS: Among young women, tumours were frequently ER negative (P=0.01) with lower ER (P<0.00), PR (P=0.03), higher ki67 index (KI) (P=0.01) and p53 (P=0.00) compared with older women. Triple negative was more frequent among young women with frequent lymph node involvement compared with older women. Luminal B among young vs old women showed lower ER (67% vs 88%), PR (32% vs 52%), higher KI (48% vs 34%) and p53 (19% vs 7%). Linear regression model showed increasing KI (P<0.0001) and p53 (P=0.0003) according to the molecular subtypes. Survival difference among subtypes was demonstrated by multivariate analysis (P=0.0092) after adjusting for age, race, tumour size, grade and stage. CONCLUSION: We demonstrated significant differences in biomarker expression relative to age and molecular subtypes. Molecular subtype defined by IHC was an independent prognostic factor. Nature Publishing Group 2012-07-10 2012-06-19 /pmc/articles/PMC3394967/ /pubmed/22713661 http://dx.doi.org/10.1038/bjc.2012.219 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Morrison, D H
Rahardja, D
King, E
Peng, Y
Sarode, V R
Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
title Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
title_full Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
title_fullStr Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
title_full_unstemmed Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
title_short Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
title_sort tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394967/
https://www.ncbi.nlm.nih.gov/pubmed/22713661
http://dx.doi.org/10.1038/bjc.2012.219
work_keys_str_mv AT morrisondh tumourbiomarkerexpressionrelativetoageandmolecularsubtypesofinvasivebreastcancer
AT rahardjad tumourbiomarkerexpressionrelativetoageandmolecularsubtypesofinvasivebreastcancer
AT kinge tumourbiomarkerexpressionrelativetoageandmolecularsubtypesofinvasivebreastcancer
AT pengy tumourbiomarkerexpressionrelativetoageandmolecularsubtypesofinvasivebreastcancer
AT sarodevr tumourbiomarkerexpressionrelativetoageandmolecularsubtypesofinvasivebreastcancer